Immunotherapy in the treatment of lymphoma

Table 4 Checkpoint inhibitor studies

Drug [Ref.]	Target	No. of patients	Study design	Study phase	Results
Nivolumab	PD-1
[84]		243	R/R cHL (after ASCT)	2	ORR/CR: 69%/40%; PFS: 14.7 mo, Grade ≥ 3 AEs: lipase increases 5%, neutropenia 3%, ALT increases 3%
[88]		61	R/R cHL with BV	1/2	ORR/CR: 82%/61%; AEs: Infusion reactions 44% (BV), corticosteroid therapy 8%
[89]		64	R/R cHL Nivo + BV, Ipi + BV, Nivo + Ipi + BV	1/2	ORR: 89%, 76%, 82% Grade ≥ 3 AEs: 16%, 42%, 50%
Pembrolizumab	PD-1
[85]		210	R/R cHL	2	ORR/CR: 69%/22.4% 6-mos DoR rate: 75.6% TRAEs: hypothyroidism 12.4%, pyrexia 10.5%
[86]		304	R/R cHL vs BV	3	PFS: 13.2 mo vs 8.3 mo (HR 0.65, P = 0.00271), ORR/CR: 65.6%/24.5% vs 54.2%/24.2% TRAEs: 19.6% vs 25%
[91]		74	R/R PMBCL	2	ORR/CR: 45%/13% DoR: NR (12.5 mo FU); Grade ≥ 3 TRAEs: 23%
[92]		24	R/R CTCL	2	ORR: 38%; IRAEs: 17%

AE: Adverse event; ALT: Alanine amino transferase; ASCT: Autologous stem cell transplantation; BV: Brentuximab vedotin; cHL: Classic Hodgkin lymphoma; CR: Complete response; CTCL: Cutaneous T-cell lymphoma; DoR: Duration of response; Ipi: Ipilimumab; IRAEs: Immune related adverse event; Nivo: Nivolumab; NR: Not reached. ORR: Objective response rate; PFS: Progression-free survival; PMBCL: Primary mediastinal B-cell lymphoma; R/R: Relapsed/refractory; TRAEs: Treatment-related adverse event.